home site map e-mail
216-831-5700 / 800-622-8521

 
Retina Associates - Research Coordinators
 
Select display options below. (Cookies need to be enabled in your browser!)
Colors: High contrast    Default    Font Size: X-Large    Large    Medium    Default    Small   
 
 
» QUICK LINKS
Select a link below for details.

» Age-related Macular Degeneration

» Diabetic Retinopathy

» Retinal Vein Occlusion

» Other Diagnoses

 
» RESEARCH & CLINICAL TRIALS

Study Detail: Pfizer Macugen

Trial Description

Summary: To test the effectiveness of Macugen on recent onset wet macular degeneration.

Basic Trial Information

Phase

Disease

Status

Age

Sponsor

Protocol #

OPEN LABEL

ARMD RECENT ONSET

ENROLLING

N/A

PFIZER

N/A

Study Duration: 54 WEEKS

Eligibility Criteria:

Inclusion Criteria:

· Best corrected VA of ≥20/80

· Evidence of subfoveal CNV secondary to ARMD

· Minimally classic and occult lesions must demonstrate signs of progression

Please check with the clincal coordinator for other inclusion criteria

                Exclusion Criteria

· Any subfoveal atrophy of fibrosis

· Blood comprising more than 50% of the lesion

· Cataract that would prevent photography.

· Past PDT or Thermal laser

Please check with the clinical coordinator for other exclusion criteria

 

Study Title : Pfizer Early AMD Lesion Study

Trial Contact Information

Site

Study Coordinator

Beachwood

Kim 216/831-5704 ext 6800